01011.HK
China NT Pharma Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.42
−1.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 54.2M | 24.2M | 38.0M | 7.4M | 207.1M |
| Cost of Revenue | 38.8M | 14.5M | 32.7M | — | 81.8M |
| Gross Profit | 15.4M | 9.6M | 5.3M | 7.4M | 125.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | 3.8M |
| SG&A Expense | 41.2M | 22.0M | 18.5M | 58.8M | 22.6M |
| General & Admin Expense | 25.2M | 13.7M | 18.5M | 58.8M | 59.9M |
| Selling & Marketing Expense | 8.3M | 8.2M | — | — | 46.2M |
| Other Expenses | — | — | — | 4.8M | 33.0K |
| Total Operating Expenses | 41.2M | 22.0M | 18.5M | 63.6M | 26.4M |
| Cost and Expenses | 79.9M | 36.5M | 51.2M | 63.6M | 26.4M |
| Operating Income (EBIT) | (25.8M) | (12.4M) | (13.2M) | (56.2M) | (26.5M) |
| Non-Operating | |||||
| Interest Income | 18.1K | 6.8K | 11.0K | 9.0K | 40.0K |
| Interest Expense | 65.8M | 27.1M | 31.5M | 28.8M | 39.4M |
| Net Interest Income | (65.8M) | (27.1M) | (31.5M) | (28.8M) | (39.3M) |
| Other Non-Op Income/Expense | (71.1M) | (13.9M) | (40.3M) | 22.8M | (23.5M) |
| Non-Operating Income (excl Interest) | — | — | 2.4M | (51.7M) | — |
| EBT (Pre-Tax Income) | (96.8M) | (26.3M) | (53.5M) | (33.4M) | (50.0M) |
| Income Tax Expense | (1.0K) | — | (123.0K) | 122.0K | 12.1M |
| Bottom Line | |||||
| Net Income | (98.2M) | (26.0M) | (53.4M) | (143.6M) | (66.4M) |
| Earnings from Cont. Ops | (96.6M) | (26.3M) | (53.4M) | (33.5M) | (50.0M) |
| Earnings from Discont. Ops | — | — | — | (110.1M) | — |
| Bottom Line Net Income | (98.2M) | (26.0M) | (53.4M) | (143.6M) | (66.4M) |
| Per Share | |||||
| Basic EPS | (HK$0.27) | (HK$0.04) | (HK$0.20) | (HK$0.73) | (HK$0.04) |
| Diluted EPS | (HK$0.27) | (HK$0.04) | (HK$0.20) | (HK$0.73) | (HK$0.04) |
| Revenue Per Share | HK$0.07 | HK$0.04 | HK$0.14 | HK$0.04 | HK$0.11 |
| Shares | |||||
| Basic Shares Outstanding | 821.5M | 616.9M | 264.1M | 197.8M | 1.9B |
| Diluted Shares Outstanding | 821.5M | 616.9M | 264.1M | 197.8M | 1.9B |
| Profitability Metrics | |||||
| EBITDA | (20.6M) | (12.3M) | (8.7M) | 1.3M | 10.4M |
| D&A | 5.2M | 48.0K | 4.6M | 5.9M | 21.1M |
| EBIT | (25.8M) | (12.4M) | (13.2M) | (4.6M) | (10.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026